APTN ADAPTIN BIO, INC.
Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1938571 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-0.4%
TTM EPS YoY30.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-452.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets253.9%
Debt / equity—
Current ratio0.39x
Interest coverage-485.91x
Cash quality & payout
Operating cash flow / net income0.58x
Accruals ratio-189.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | — | — | — |
| R&D expense | $1.77M | $1.82M | — |
| SG&A expense | $3.64M | $745,294 | $85,593 |
| Operating income | -$5.41M | -$2.57M | -$85,593 |
| Interest expense | $72,659 | $341,048 | — |
| Pretax income | -$5.17M | -$3.12M | — |
| Net income | -$5.17M | -$3.12M | -$85,593 |
| EPS (basic) | -0.66 | -0.96 | -0.02 |
| EPS (diluted) | -0.66 | -0.96 | -0.02 |
| Weighted avg. shares (diluted) | 7.81M | 3.25M | 5.00M |
| Balance sheet | |||
| Cash & equivalents | $459,174 | $34,085 | $4,754 |
| Current assets | $619,159 | $45,539 | $380 |
| Total assets | $619,159 | $239,415 | $380 |
| Current liabilities | $2.11M | $4.34M | $113,277 |
| Total liabilities | $2.11M | $4.34M | $113,277 |
| Shareholders' equity | -$1.49M | -$4.10M | -$977,559 |
| Shares outstanding | 8.66M | 3.25M | 5.00M |
| Cash flow statement | |||
| Operating cash flow | -$4.78M | -$649,283 | -$81,035 |
| Financing cash flow | $5.20M | $678,614 | $80,915 |
| Stock-based compensation | $496,864 | — | — |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.